



Hybrid Event

*International Symposium
on Targeting Homologous
Recombination Deficiency
in Cancer*

From Bench to Clinic 2025

26-27 06 2025

Conference Venue **BRFAA**

BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS, GREECE

**Scientific
Program**

Secretariat



Scientific | Cultural Events & Publications

T +30 210 7240039 F +30 210 7240139

E info@scep.gr www.scep.gr



Organized
by



Welcome letter

Dear Friends and Colleagues,

It is our great pleasure to welcome you to the **International Symposium on Homologous Recombination and DNA Repair: From Bench to Clinic 2025**, taking place on **June 26–27, 2025**, at the **Biomedical Research Foundation of the Academy of Athens**.

This symposium will bring together speakers from Greece and abroad, covering a wide range of expertise, including clinical and laboratory medicine, basic science, diagnostics, and the private sector. The event will explore fundamental aspects of **DNA repair, with a focus on homologous recombination**, molecular tools for identifying tumours with DNA repair deficiencies, and the latest clinical advancements in the field.

Key topics include:

- **Basic biology of DNA damage response**, with an emphasis on homologous recombination
- **Development of inhibitors leveraging synthetic lethality**
- **Current and emerging methodologies** for detecting homologous recombination deficiency for patient stratification
- **Clinical applications** of DNA repair inhibitors, alone or in combination with other therapies, across various tumour types.

We warmly welcome scientists, clinicians, students, and healthcare professionals interested in DNA repair to join us for this exciting event.

Warm regards,

The Organizing Committee

Pr. A. Klinakis

PhD, Biochemical Research
Foundation Academy of Athens
(BRFAA), GR

Dr. P. Constantoulakis

PhD, GENOTYPOS MSA,
Athens, GR

Pr. W. Niedzwiedz

PhD, The Institute of
Cancer Research,
London, UK

Dr. J. Loizou

PhD, The Institute of
Cancer Research,
London, UK

Dr. S. Linardopoulos

PhD, Oncology AstraZeneca,
Cambridge, UK

Thursday, June 26, 2025

08.00-08.15: Registration

08.15-08.30: **Welcome address**

A. Klinakis (GR)

08.30-10.10: Basic Research Session (I)

Chairs: **A. Klinakis (GR)**, **Th. Rampias (GR)**

08.30-08.50: DNA resection, ssDNA gaps and PARP inhibitor sensitivity:
Mechanisms and therapeutic opportunities **W. Niedzwiedz (UK)**

08.50-09.10: DNA damage and innate immune responses in health and disease **G. Garinis (GR)**

09.10-09.30: Beyond BRCA: why PARP inhibitors also kill ATM-deficient cancer cells **R. Chapman (UK)**

09.30-09.50: Immune TME landscape of HRD tumors and their dynamics during cancer evolution **D. Dangaj (CH)**

09.50-10.10: Discussion

10.10-10.40: Invited Lecture

Chair: **V. Georgoulas (GR)**

Germline and Somatic mutation rate

S. Antonarakis (CH)

10.40-11.00: **Coffee break**

11.00-12.50: Methodologies and Diagnostics Session

Chairs: **P. Constantoulakis (GR)**, **G. Nasioulas (GR)**

11.00-11.20: How do you assess homologous recombination (validated clinically)	G. Christopoulou (GR)
--	------------------------------

11.20-11.40: Technical aspects and clinical applications of HRD testing based on AmoyDx pipelines
(Molecular Pathologist perspectives) **U. Malapelle (IT)**

11.40-12.00: Utilizing Pillar Biosciences' Rapid oncoReveal 4-Gene Methylation Panel to guide the expanded use of PARPi therapy in breast cancer patients **E.Christoforou (UK)**

12.00-12.20: HRD Testing in Ovarian Cancer: A Molecular Pathologist's Perspective

12.20-12.40: Validating and Selecting the Optimal HRD Assay within a Comprehensive Genomic Profiling (CGP) Panel? **E. Papadopoulou (GR)**

12.40-12.50: Discussion

12.50-13.20: Keynote Lecture

Chair: **J. Loizou (UK)**

Genome organization in DNA repair pathway choice and mutagenesis

E. Soutoglou (UK)

13.20-14.30: Light Lunch

14.30-16.20: Basic Research Session (II)

Chairs: **W. Niedzwiedz (UK), V. Anastasopoulou (GR)**

14.30-14.50: Mechanisms of sensitivity of cancer cells to ATR and CHK1 inhibitors

Th. Halazonetis (CH)

14.50-15.10: Signaling replication stress and DNA damage beyond cell boundaries

Ph. Pasero (FR)

15.10-15.30: Epigenetic regulation of DDR

A. Klinakis (GR)

15.30-15.50: Inherited DNA repair deficiencies

G. Stewart (UK)

15.50-16.10: Replication stress of CNV in HRD tumors

Th. Rampias (GR)

16.10-16.20: Discussion

Friday, June 27, 2025

08.30-10.00: PARP inhibitors in clinic: Clinical state of the art

Chair: **V. Georgoulas (GR)**

08.30-08.50: Updating the therapeutic use of PARPi in ovarian cancer

R. Zakopoulou (GR)

08.50-09.10: Updating the therapeutic use of PARPi in breast cancer

E. Fountzila (GR)

09.10-09.30: Updating the therapeutic use of PARPi in prostate cancer

M. Lontos (GR)

09.30-09.50: Is agnostic treatment of HRD/GSS-positive tumors with PARPi a therapeutic step forward?

V. Anastasopoulou (GR)

09.50-10.00: Discussion

10.00-11.10: Biology: Resistance to PARPi

Chairs: **Th. Rampias (GR), P. Constantoulakis (GR)**

10.00-10.20: Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy

J. Loizou (UK)

10.20-10.40: ATR inhibitor-based combinations to overcome PARP inhibitor resistance

I. Gounaris (DE)

10.40-11.00: AI Biomarkers of Genomic Instability in Triple Negative Breast Cancer

S.J. Sammut (UK)

11.00-11.10: Discussion

11.10-11.30: Coffee Break

11.30-13.00: Early clinical trials Session

Chairs: **S. Linardopoulos (UK), P. Constantoulakis (GR)**

11.30-11.50: Homologous recombination status of platinum responsive advanced triple negative breast cancers treated with olaparib +/- Durvalumab maintenance therapy (Clinical perspective)

T. Tan (US)

11.50-12.10: Discovery and preclinical characterisation of saruparib (AZD5305), a PARP1-selective inhibitor and trapper

M. Albertella (UK)

12.10-12.30: First-in-human Phase 1/2a trial of the first-in-class new PARP1 inhibitor saruparib in patients with advanced solid tumours with HRR mutations

S. Linardopoulos (UK)

12.30-12.50: Tuvusertib (ATR inhibitor) in combination with niraparib or lartesertib (ATM inhibitor): initial safety and efficacy from Ph1b studies

I. Gounaris (DE)

12.50-13.00: Discussion

13.00-14.00: **Light Lunch**

14.00-15.10: **Basic Research Session**

Chairs: **A. Klinakis (GR), Th. Rampias (GR)**

14.00-14.20: Ovarian cancer testing in the UK-a genomics perspective **G. Burghel (UK)**

14.20-14.40: Telomeric instability in homologous recombination deficiency
and cancer **S. Gagos (GR)**

14.40-15.00: The evolution of combinatorial treatment with PARPi **M. Sideridou (GR)**

15.00-15.10: Discussion

15.10: **Closing remarks**

Faculty

Albertella M. D Phil, Senior Director, Bioscience, AstraZeneca Oncology R&D, Cambridge, UK

Anastasopoulou V. Postdoctoral Researcher, Hellenic Oncology Research Group, Athens, Greece

Antonarakis S. Professor Emeritus, University of Geneva Medical School, Switzerland / MediGenome, Swiss Institute of Genomic Medicine, Geneva, Switzerland

Burghel G. Consultant Clinical Scientist, North West Genomic Laboratory Hub) / Honorary Senior Lecturer, University of Manchester, UK

Chapman R. MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK

Christoforou E. Senior Scientist, AstraZeneca, Early Oncology R&D, Translational Medicine Epigenomics, UK

Christopoulou G. MSc, PhD, Lab Director, Head of Genetics & Genomics Dpt, Genotypos S.A.

Constantoulakis P. PhD, Scientific Director, Genotypos MSA, Greece

Dangaj D. PhD, Privat Docent (Lecturer), Group Leader, Laboratory Tumor Microenvironment and Biomarker Discovery, Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, Switzerland

Fountzila E. Medical Oncologist, Clinical Associate Professor, European University Cyprus, St Lukes Hospital, Thessaloniki, Greece

Gagos S. Principal Investigator Biomedical Research Foundation of the Academy of Athens (BRFAA), Greece

Garinis G. Professor of Genetics, Department of Biology, University of Crete, Affiliated Group leader at IMBB-FORTH, Greece

Georgoulas V. Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Greece

Gounaris I. MD, PhD, VP, Head of Clinical Development DNA Damage Response (DDR), Merck KGaA

Guerini Rocco E. Associate Professor of Pathology, Department of Oncology and Hemato-Oncology, University of Milan, and Chair of Molecular Pathology Unit, Division of Pathology, European Institute of Oncology, IRCCS, Milano, Italy

Halazonetis Th. Professor, Dept of Molecular and Cellular Biology, University of Geneva, Switzerland

Klinakis A. PhD, Investigator - Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece

Linardopoulos S. Director, Translational Science, Oncology AstraZeneca, Cambridge, UK

Liontos M. Assistant Professor, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece

Loizou J. Group Leader Divisions of Cancer Therapeutics and Breast Cancer Research | Deputy Director Centre for Target Validation, The Institute of Cancer Research, UK

Malapelle U. Associate Professor in School of Medicine, Chair of Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples, Naples, Italy

Nasioulas G. PhD, Chief Scientific Officer, Genekor Medical S.A. Greece

Niedzwiedz W. Professor, PhD, Genome Instability and Cancer Team, The Institute of Cancer Research, London, UK

Papadopoulou E. PhD, International Laboratory Director, Genekor Medical S.A., Greece

Pasero Ph. Institute of Human Genetics, CNRS and University of Montpellier, France

Rampias Th. PhD, Investigator - Assistant Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece

Sammut S.J. MD, PhD, Group Leader, Cancer Dynamics Lab, Consultant Medical Oncologist, The Royal Marsden Hospital, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Chester Beatty Laboratories, London, UK

Sideridou M. Postdoc Researcher, Biochemical Research Foundation Academy of Athens (BRFAA), Greece

Soutoglou E. Professor of Genome Stability, Genome Damage and Stability Centre, Sussex University, School of Life Sciences, University of Sussex, Brighton, UK

Stewart G. Professor, Department of Cancer and Genomic Sciences, University of Birmingham, UK

Tan T. Senior Consultant Medical Oncologist, National Cancer Centre Singapore

Zakopoulou R. MD, PhD, Medical Oncologist, Locum Consultant, General Anticancer Hospital "Agioi Anargyroi", Athens, Greece

Info

Organized by



Hellenic Oncology Research Group

Date

26-27 June, 2025

Venue

The Biomedical Research Foundation of the Academy of Athens (BRFAA)
4, Soranou Ephessiou Str., Holargos

Hybrid Event

You can watch the Hybrid Event online through the link www.livetime.gr and ask written questions throughout the presentations

Registration

Free

Certificate of Attendance

The certificate of attendance will be given to the participants at the end of the event.

Secretariat SCEP*

Scientific | Cultural Events and Publications

T +30 210 7240039 **E** info@scep.gr

www.scep.gr   



Scientific | Cultural Events & Publications

T +30 210 7240039 **F** +30 210 7240139

E info@scep.gr www.scep.gr

